The 2015 world health organization classification of tumors of the pleura: Advances since the 2004 Classification

Journal of Thoracic Oncology

Volumn 11, Issue 2, 2016, Pages 142-154

  Galateau Salle, Francoise ^a,b   Churg, Andrew ^c   Roggli, Victor ^d   Travis, William D ^e  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

b catenin; BAP1; Biphasic; CTNNB1 gene mutations; Desmoid; Desmoplastic; Epithelioid; Epithelioid hemangioendothelioma; Grading; Mesothelioma; p16; Sarcomatoid; Solitary fibrous tumor; STAT6; WWTR1 CAMTA1

Indexed keywords

BETA CATENIN; BRCA1 PROTEIN; STAT6 PROTEIN; BAP1 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; CAMTA1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; SIGNAL PEPTIDE; STAT6 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE; WWTR1 PROTEIN, HUMAN;

CANCER CLASSIFICATION; CANCER MORPHOLOGY; CANCER PATIENT; CLINICAL PRACTICE; DESMOID TYPE FIBROMATOSIS; EPITHELIOID HEMANGIOENDOTHELIOMA; EPITHELIOID MESOTHELIOMA; FIBROMATOSIS; GENE FUSION; GENE MUTATION; HEMANGIOENDOTHELIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INVESTIGATIVE PROCEDURES; MALIGNANT MESOTHELIOMA; OBSERVATIONAL STUDY; PLEURA TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMATOID MESOTHELIOMA; SOLITARY FIBROUS TUMOR; WELL DIFFERENTIATED PAPILLARY MESOTHELIOMA; WORLD HEALTH ORGANIZATION; WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE PLEURA; CANCER GRADING; CHEMISTRY; CLASSIFICATION; GENETICS; MESOTHELIOMA; PATHOLOGY;

BETA CATENIN; CALCIUM-BINDING PROTEINS; GENE FUSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MESOTHELIOMA; NEOPLASM GRADING; PLEURAL NEOPLASMS; STAT6 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; WORLD HEALTH ORGANIZATION;

EID: 84958958429     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.11.005     Document Type: Review

References (58)

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer; 2015.
2. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015;10:1240-1242.
3. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer; 2004.
4. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196:23-32.
5. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association for the Study of Lung Cancer Mesothelioma database. J Thorac Oncol. 2012;7:1631-1639.
6. Brcic L, Jakopovic M, Brcic I, et al. Reproducibility of histological subtyping of malignant pleural mesothelioma. Virchows Arch. 2014;465:679-685.
7. Ordonez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol. 2012;25:1011-1022.
8. Kadota K, Suzuki K, Sima CS, et al. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: A clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol. 2011;6:896-904.
9. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:647-667.
10. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.
11. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol. 2006;19:417-428.
12. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: A clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470-479.
13. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21:1084-1094.
14. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27: 390-395.
15. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129:1421-1427.
16. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39:977-982.
17. Hwang H, Tse C, Rodriguez S, Gown A, Churg A. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. AmJ Surg Pathol. 2014;38:681-688.
18. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012;136:1217-1226.
19. Churg A, Cagle P, Colby TV, et al. The fake fat phenomenon in organizing pleuritis: A source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol. 2011;35:1823-1829.
20. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183-1200.
21. Mangano WE, Cagle PT, Churg A, Vollmer RT, Roggli VL. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: A histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol. 1998;110:191-199.
22. Thway K, Wang J, Wren D, et al. The comparative utility of fluorescence in situ hybridization and reverse transcriptionpolymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma. Virchows Arch. 2015;467:217-224.
23. Galateau-Sallé F, Vignaud JM, Burke L, et al. Welldifferentiated papillary mesothelioma of the pleura: A series of 24 cases. Am J Surg Pathol. 2004;28:534-540.
24. Churg A, Allen T, Borczuk AC, et al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol. 2014;38:990-998.
25. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: Analysis of a series and review of the literature. Histopathology. 2007;51:509-554.
26. Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49:560-568.
27. Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25:260-271.
28. Krasinskas AM, Borczuk AC, Hartman DJ, et al. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. 2015 Aug 14. http://dx.doi.org/10.1111/his.12807.
29. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742-747.
30. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135:619-627.
31. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
32. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139:39-46.
33. Hida T, Matsumoto S, Hamasaki M, et al. p16 deletion status in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue [epub ahead of print]. Cancer Sci. http://dx.doi.org/10.1111/cas.12769, accessed December 21, 2015.
34. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138:137-144.
35. Paintal A, Raparia K, Zakowski MF, Nayar R. The diagnosis of malignant mesothelioma in effusion cytology: A reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013;121:703-707.
36. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627-635.
37. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970-2979.
38. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668-672.
39. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-1025.
40. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-Type malignant mesothelioma. Cancer Sci. 2012;103:868-874.
41. Zauderer MG, Bott M, McMillan R, et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol. 2013;8:1430-1433.
42. Cheung M, Talarchek J, Schindeler K, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013;206:206-210.
43. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43:1018-1021.
44. Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-Associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043-1057.
45. McGregor SM, Dunning R, Hyjek E, et al. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015;46:1670-1678.
46. Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: Are we there yet? [e-pub ahead of print]. Arch Pathol LabMed. 2015 Aug 19. accessedDecember 21, 2015.
47. Chmielecki J, Crago AM, Rosenberg M, et al. Wholeexome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45: 131-132.
48. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180-185.
49. Demicco EG, Harms PW, Patel RM, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015;143:672-682.
50. Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3:98ra82.
51. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644-653.
52. Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol. 2001;25:684-687.
53. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775-784.
54. Anderson T, Zhang L, Hameed M, et al. Thoracic epithelioid malignant vascular tumors: A clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol. 2015;39:132-139.
55. Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140:1312-1318.
56. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68-74.
57. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. Cancer. 2013;119:3696-3702.
58. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.